Zura Bio Limited (NASDAQ:ZURA) Short Interest Update

Zura Bio Limited (NASDAQ:ZURA) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 3,440,000 shares, a growth of 92.2% from the July 15th total of 1,790,000 shares. Based on an average daily volume of 283,700 shares, the short-interest ratio is currently 12.1 days. Approximately 10.4% of the company’s stock are short sold.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZURA shares. Oppenheimer lifted their target price on Zura Bio from $16.00 to $21.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Piper Sandler started coverage on Zura Bio in a report on Friday, May 3rd. They issued an “overweight” rating and a $26.00 target price for the company. Finally, Cantor Fitzgerald assumed coverage on Zura Bio in a report on Wednesday, June 12th. They issued an “overweight” rating on the stock. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $19.75.

Insider Activity at Zura Bio

In other news, Director Van Amstel Arnout Ploos bought 80,000 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was bought at an average price of $6.20 per share, for a total transaction of $496,000.00. Following the transaction, the director now owns 100,000 shares in the company, valued at $620,000. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 15.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zura Bio

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC grew its position in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. Forefront Analytics LLC raised its holdings in shares of Zura Bio by 46.8% in the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after buying an additional 6,765 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Zura Bio by 15.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after buying an additional 6,412 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in Zura Bio in the 1st quarter valued at about $1,157,000. Finally, Armistice Capital LLC raised its stake in shares of Zura Bio by 15.4% in the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after acquiring an additional 244,000 shares during the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Trading Down 2.4 %

ZURA stock opened at $3.29 on Wednesday. Zura Bio has a 1-year low of $2.00 and a 1-year high of $7.63. The business’s 50 day moving average is $3.65 and its 200-day moving average is $3.76.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.